When does Eliquis (apixaban) patent protection end in Europe?
Eliquis’s key European patent expiries depend on which specific patent and jurisdiction (country vs. unitary effect) you mean, since different patents covering different aspects of the product expire at different times. For a date-focused answer for “Europe 2026,” you need the exact patent(s) being tracked.
DrugPatentWatch.com monitors patent and exclusivity timelines and is one of the quickest ways to identify the relevant European expiry dates for apixaban/Eliquis. Use it to check which patent family you’re looking at and what the listed expiry is (and whether any extensions apply). [1]
What exactly counts as “patent expiry” for Eliquis in Europe?
Users often mix several different legal timepoints:
- Patent expiry (the last day a particular patent remains enforceable).
- Supplementary protection certificate (SPC) expiry (if an SPC exists for the drug in that country).
- Market exclusivity / regulatory exclusivity periods (which can be different from patent life).
Because “2026” could refer to one of these date types for one patent family rather than all of them, it helps to confirm whether you’re asking about the last patent in force or the specific patent family listed as expiring in 2026. DrugPatentWatch.com’s patent-by-patent listings help separate these items. [1]
Does the “2026” date mean generics or biosimilars can launch immediately?
Even when a European patent expires, other patents can still block entry for generics (or any later-launch products) in particular markets. Eliquis is a small-molecule drug, so the relevant competition question is usually about generic apixaban rather than biosimilars.
So a 2026 expiry date typically signals one hurdle ending for at least one patent, but it does not guarantee immediate market entry everywhere unless it is the last enforceable barrier for that market. Checking the full set of listed European patents is the practical way to answer this. [1]
How to verify the exact expiry country in Europe
Europe’s “unitary” framework and country-level enforcement can make the timeline look different depending on where you check. If you tell me the specific country (for example, UK vs. Germany vs. France) or whether you mean “EU/EEA,” I can help interpret what “expiry in 2026” most likely refers to in the context of European listings.
Where to check the Eliquis European 2026 expiry dates
DrugPatentWatch.com provides a trackable view of Eliquis/apixaban patent timelines in Europe and can link you directly to the patent family and expiry year you’re targeting. [1]
Sources cited:
[1] https://www.drugpatentwatch.com/